Fears R, Rush W R, Walker P, Ferres H
Biochem Pharmacol. 1984 Jan 15;33(2):209-17. doi: 10.1016/0006-2952(84)90478-7.
Administration of BRL 26314 [N-(4-chlorobenzyl)-L-phenylalanine] raises circulating high-density lipoprotein (HDL) cholesterol and lowers total triglyceride levels in rats whether maintained on stock or semi-synthetic diets. HDL is also elevated by BRL 26314 in hypothyroid rats and in rats with pre-existing hyperlipidaemia where aortic total cholesterol concentration is decreased. BRL 26314 promotes the excretion of a dose of radiolabelled cholesterol as faecal sterols and bile acids, and decreases the extent of cholesterol-radiolabelling in tissue pools, particularly the aorta and adipose tissue. The increase in cholesterol and bile acid (cholic acid) turnover distinguishes BRL 26314 from a cholestatic agent such as 1-naphthyl isothiocyanate where a superficially similar change in HDL concentration disguises an impaired cholesterol transport. BRL 26314 is not a general protein inducer but part of the mechanism of action may involve enhancement of white adipose tissue lipoprotein lipase activity.
给予BRL 26314 [N-(4-氯苄基)-L-苯丙氨酸]可提高大鼠循环中的高密度脂蛋白（HDL）胆固醇水平，并降低总甘油三酯水平，无论大鼠食用的是普通饲料还是半合成饲料。在甲状腺功能减退的大鼠以及已有高脂血症且主动脉总胆固醇浓度降低的大鼠中，BRL 26314也可提高HDL水平。BRL 26314可促进一定剂量放射性标记胆固醇以粪便固醇和胆汁酸的形式排出，并降低组织库中胆固醇的放射性标记程度，尤其是主动脉和脂肪组织。胆固醇和胆汁酸（胆酸）周转率的增加使BRL 26314有别于诸如1-萘基异硫氰酸酯之类的胆汁淤积剂，在后者中，HDL浓度表面上类似的变化掩盖了胆固醇转运受损的情况。BRL 26314不是一种一般的蛋白质诱导剂，但其作用机制的一部分可能涉及增强白色脂肪组织脂蛋白脂肪酶的活性。
